Learning Objectives:

To review the rationale for population prostate cancer screening focusing on the role of MRI.
To show that harm reduction benefits of MRI are retained in lowdisease prevalence screening, without impairing the detection of clinically meaningful cancers.
To understand the need for optimization of the MRI examination and challenges for the MRI pathway in population screening settings.

ERROR: please note the GG2 prevalence stated at minute 24 .. should read 32% (=735/2293). Sorry about that.

The takehome points are:

MRI lowers the harm of overdiagnosis after PSA testing in population screening at baseline. Will MRI continue to be effective through multiple rounds of screening?
Age, agespecific PSA levels, racial profile, and family history are important when deciding whom to investigate
In highincome communities, information from polygenic risk scores and MRI will aid in biopsy decisions
MRIcentered screening can be clinically effective (reducing harm) and costefficient
Multiple MRI optimization and pathway challenges need to be addressed
Highquality & consistency of MRI interpretations and biopsy performance across diagnostic centers are the most critical problems that need addressing